Immunotherapy: a new era for hepatocellular carcinoma

Abstract

Cancer is a major disease threatening human health. The overall prognosis for hepatocellular carcinoma (HCC) patients is poor, with a dismal 5-year survival rate of approximately 5%-30%. The dysfunction of immune system plays a pivotal role in the development of cancer, which has attracted attention of several researchers. Recent advances in immunotherapy have led to various inspired achievements and refreshed our concepts about cancer treatments. In this article, several types of immune-based therapies for treating HCC are reviewed. Their underlying mechanisms, preclinical and clinical study results, potential prospects, and deficiencies are discussed, and an outline for future research directions is proposed.

Keywords

Hepatocellular carcinoma / immunotherapy / cancer treatments

References

[1] All Cancers (excluding non-melanoma skin cancer) Estimated Incidence, Mortality and Prevalence Worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. [Last accessed on 18 Jul 2018].

[2] Allemani C,Di Carlo V,Matz M,Bonaventure A,Johnson CJ,Ogunbiyi OJ,Chen WQ,Engholm G,Monnereau A,Visser O,Aitken J,Coleman MP.Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.Lancet2018;391:1023-75

[3] Wherry EJ.Molecular and cellular insights into T cell exhaustion.Nat Rev Immunol2015;15:486-99 PMCID:PMC4889009

[4] Speiser DE,Verdeil G.Regulatory circuits of T cell function in cancer.Nat Rev Immunol2016;16:599-611

[5] Gabrielson A,Wang H,Kallakury B,Reddy S,Fishbein T,Island E,Banovac F,Kachhela J,Zhang T,Prins P,Marshall J,Atkins M.Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC.Cancer Immunol Res2016;4:419-30 PMCID:PMC5303359

[6] Zhou J,Sun H,Xu L,Tong JH,Chong CCN,Wang HK,Goodwin T,Huang L,Sung JJ,To KF.Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.Gut2018;67:931-44

[7] Mok MT,Tang W,Oliver AW,Cheng AS.CCRK is a novel signalling hub exploitable in cancer immunotherapy.Pharmacol Ther2018;186:138-51

[8] Chiu DK,Xu IM,Lai RK,Koh HY,Wei LL,Ng IO.Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma.Nat Commun2017;8:517 PMCID:PMC5593860

[9] Harding JJ,Abou-Alfa GK.Immunotherapy in hepatocellular carcinoma: primed to make a difference?.Cancer2016;122:367-77

[10] Longo V,Casadei Gardini A,Licchetta A,Memeo R,Aprile G,Nardulli P,Brunetti O.Immunotherapeutic approaches for hepatocellular carcinoma.Oncotarget2017;8:33897-910 PMCID:PMC5464921

[11] Ott PA,Keskin DB,Sun J,Zhang W,Giobbie-Hurder A,Chen C,Carter TA,Lieb DJ,Gjini E,Lane WJ,Nellaiappan K,Daley H,Buchbinder EI,Harden M,Gabriel S,Barouch DH,Getz G,Neuberg D,Lander ES,Hacohen N.An immunogenic personal neoantigen vaccine for patients with melanoma.Nature2017;547:217-21 PMCID:PMC5577644

[12] Sahin U,Miller M,Simon P,Bukur V,Luxemburger U,Omokoko T,Albrecht C,Kuhn AN,Heesch S,Müller F,Vogler I,Attig S,Breitkreuz A,Suchan M,Hohberger A,Diekmann J,Waksmann O,Witt M,Rothermel A,Langer D,Diken M,Nemecek R,Grabbe S,Utikal J,Loquai C.Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.Nature2017;547:222-6

[13] Robbins PF,El-Gamil M,Gross C,Lin JC,Cliften P,Samuels Y.Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.Nat Med2013;19:747-52 PMCID:PMC3757932

[14] Gros A,Tran E,Robbins PF,Prickett TD,Crystal JS,Trebska-McGowan K,Yang JC.Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.Nat Med2016;22:4051

[15] Rosenberg SA.Adoptive cell transfer as personalized immunotherapy for human cancer.Science2015;348:62-8

[16] Tran E,Lu YC,Gartner JJ,Pasetto A,Ray S,Kriley IR.T-cell transfer therapy targeting mutant KRAS in cancer.N Engl J Med2016;375:2255-62 PMCID:PMC5178827

[17] FDA approval brings first gene therapy to the United States. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm. [Last accessed on 18 Jul 2018].

[18] FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm581216.htm?from=timeline&isappinstalled=0. [Last accessed on 18 Jul 2018].

[19] Tran E,Urba WJ.A milestone for CAR T cells.N Engl J Med2017;377:2593-6

[20] Bhattacharya N,Prestwood TR,DiMaio MA,Krois CR,Pham TD,Tolentino L,Hulett R,Winer D,Engleman EG.Normalizing microbiota-induced retinoic acid deficiency stimulates protective CD8+ T cell-mediated immunity in colorectal cancer.Immunity2016;45:641-55 PMCID:PMC5132405

[21] Governa V,Mele V,Amicarella F,Muraro MG,Droeser R,Bolli M,Oertli D,Terracciano LM,Spagnoli GC.The interplay between neutrophils and CD8+ T cells improves survival in human colorectal cancer.Clin Cancer Res2017;23:3847-58

[22] Horikawa N,Matsumura N,Baba T,Yoshioka Y,Konishi I.Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells.Clin Cancer Res2017;23:587-99

[23] Wang ZQ,Derocher H,Nelson BH.CD103 and intratumoral immune response in breast cancer.Clin Cancer Res2016;22:6290-7

[24] Meng WS,Ribas A,Heller JB,Glaspy JA,Economou JS.Alpha-fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination.Cancer Res2001;61:8782-6

[25] Butterfield LH,Koh A,Ribas A,Faull K,McBride WH.T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.J Immunol2001;166:5300-8

[26] Butterfield LH,Meng WS,Amarnani S,Seja E,Glaspy JA,Economou JS.T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.Clin Cancer Res2003;9:5902-8

[27] Butterfield LH,Dissette VB,Yang JQ,Duran SD,Seja E,McBride WH,Glaspy JA.A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.Clin Cancer Res2006;12:2817-25

[28] Thimme R,Boettler T,Kersting N,Makowiec F,Hopt UT,Spangenberg HC.Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma.Hepatology2008;48:1821-33

[29] Nakagawa H,Kobayashi E,Hamana H,Kishi H,Yamashita T,Terashima T,Fushimi K,Kaneko S.Association between high-avidity T-cell receptors, induced by α-fetoprotein-derived peptides, and anti-tumor effects in patients with hepatocellular carcinoma.Gastroenterology2017;152:1395-406.e10

[30] Hong Y,Guo ZS,Pang J,Mivechi NF,Bartlett DL.Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma.Hepatology2014;59:1448-58 PMCID:PMC4151349

[31] Wu S,Peng Y,Hong Y,Dong D,Merchen T,Guo ZS,Fu N.The antitumor effects of vaccine-activated CD8+ T cells associate with weak TCR signaling and induction of stem-like memory T cells.Cancer Immunol Res2017;5:908-19

[32] Zhu W,Wang L,Jiang X,Liu H,Wu J,Merchen T,He Y.Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy.Hepatology2018;

[33] Yadav M,Phung QT,Tanguay J,Franci C,Fritsche J,Modrusan Z,Lill JR.Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.Nature2014;515:572-6

[34] Sabado RL,Bhardwaj N.Dendritic cell-based immunotherapy.Cell Res2017;27:74-95 PMCID:PMC5223236

[35] Sancho D,Keller AM,Martínez D,Rosewell I.Identification of a dendritic cell receptor that couples sensing of necrosis to immunity.Nature2009;458:899-903 PMCID:PMC2671489

[36] Cuadros C,Lollini PL,Mittler RS,Lustgarten J.Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice.Int J Cancer2005;116:934-43

[37] Gallimore A.Regulatory T cells and tumour immunity - observations in mice and men.Immunology2008;123:157-63 PMCID:PMC2433304

[38] Palucka K.Human dendritic cell subsets in vaccination.Curr Opin Immunol2013;25:396-402 PMCID:PMC3711217

[39] Anguille S,Lion E,Berneman ZN.Clinical use of dendritic cells for cancer therapy.Lancet Oncol2014;15:e257-67

[40] Ahmed MS.Dendritic cell-based therapeutic cancer vaccines: past, present and future.Clin Exp Vaccine Res2014;3:113-6 PMCID:PMC4083062

[41] Anguille S,Bryant C,Goossens H,Fromm PD,Van Tendeloo VF.Dendritic cells as pharmacological tools for cancer immunotherapy.Pharmacol Rev2015;67:731-53

[42] Lion E,Berneman ZN.NK cells: key to success of DC-based cancer vaccines?.Oncologist2012;17:1256-70 PMCID:PMC3481891

[43] Butterfield LH.Dendritic cells in cancer immunotherapy clinical trials: are we making progress?.Front Immunol2013;4:454 PMCID:PMC3861778

[44] Choi YJ,Park YS,Yang KM.EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells.PLoS One2018;13:e0190638 PMCID:PMC5752035

[45] Su H,Zheng L,Zhang L.Immunotherapy based on dendritic cells pulsed with CTPFoxM1 fusion protein protects against the development of hepatocellular carcinoma.Oncotarget2016;7:48401-11 PMCID:PMC5217026

[46] Mitchell DA,Gunn MD,Sanchez-Perez L,Congdon KL,Archer GE,Friedman AH,Herndon JE2nd,McLendon RE,Vredenburgh JJ,Sampson JH.Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.Nature2015;519:366-9 PMCID:PMC4510871

[47] Kranz LM,Haas H,Loquai C,Meng M,Vascotto F,Grunwitz C,Hüsemann Y,Kuhn AN,Derhovanessian E,Attig S,Jabulowsky RA,Hassel J,Grabbe S,Türeci Ö.Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.Nature2016;534:396-401

[48] Lu Z,Jing R,Rao Q,Qi H,Yin H.Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models.J Hepatol2017;67:739-48

[49] Dannull J,Archer G,Boczkowski D,De Rosa N,Mosca PJ,Selim MA,Sampson J,Pruitt SK.Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.J Clin Invest2013;123:3135-45 PMCID:PMC3696565

[50] Lee JM,Garon E,Salehi-Rad R,Schaue D,Rosen F,Walser TC,Park SJ,Marincola FM,Abtin F,Reckamp KL,Wallace WD,Zeng G,Sharma S.Phase I trial of intratumoral injection of CCL21 gene modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8+ T-cell infiltration.Clin Cancer Res2017;23:4556-68

[51] Sfanos KS,Meeker AK,Isaacs WB.Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+..Prostate2009;69:1694-703 PMCID:PMC2782577

[52] Matsuzaki J,Mhawech-Fauceglia P,Miller A,Eppolito C,Lele S,Old LJ.Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.Proc Natl Acad Sci U S A2010;107:7875-80 PMCID:PMC2867907

[53] Fourcade J,Benallaoua M,Luescher IF,Kirkwood JM,Zarour HM.Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.J Exp Med2010;207:2175-86 PMCID:PMC2947081

[54] Paulos CM.Putting the brakes on BTLA in T cell-mediated cancer immunotherapy.J Clin Invest2010;120:76-80 PMCID:PMC2798708

[55] Cai G.The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.Immunol Rev2009;229:244-58

[56] Chambers CA,Egen JG.CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.Annu Rev Immunol2001;19:565-94

[57] Callahan MK,Allison JP.Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.Semin Oncol2010;37:473-84 PMCID:PMC3008567

[58] Wolchok JD,Weber JS,Urba WJ,O'Day SJ,Humphrey R,Lonberg N.Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.Ann N Y Acad Sci2013;1291:1-13 PMCID:PMC3910157

[59] Sangro B,de la Mata M,Garralda E,Riezu-Boj JI,Alfaro C,Lasarte JJ,Melero I.A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.J Hepatol2013;59:81-8

[60] Duffy AG,Makorova-Rusher O,Wedemeyer H,Davis JL,Heller T,Uppala A,Kleiner DE,Venzon D,Venkatesan AM,Abi-Jaoudeh N,Wood BJ.Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.J Hepatol2017;66:545-51 PMCID:PMC5316490

[61] Dong H,Tamada K.B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.Nat Med1999;5:1365-9

[62] Latchman Y,Chernova T,Borde M,Iwai Y,Brown JA,Greenfield EA,Boussiotis VA,Carreno BM,Nishimura H,Honjo T,Freeman GJ.PD-L2 is a second ligand for PD-1 and inhibits T cell activation.Nat Immunol2001;2:261-8

[63] Keir ME,Guleria I,Qipo A,Koulmanda M,Sayegh MH.Tissue expression of PD-L1 mediates peripheral T cell tolerance.J Exp Med2006;203:883-95 PMCID:PMC2118286

[64] Baumeister SH,Dranoff G.Coinhibitory pathways in immunotherapy for cancer.Annu Rev Immunol2016;34:539-73

[65] Butte MJ,Phamduy TB,Freeman GJ.Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.Immunity2007;27:111-22 PMCID:PMC2707944

[66] Topalian SL,Anders RA.Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.Nat Rev Cancer2016;16:275-87 PMCID:PMC5381938

[67] Zhou G,Boor PPC,Schutz H,Pedroza-Gonzalez A,de Jonge J,Dong H,Pan Q,Bruno MJ.Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas.Gastroenterology2017;153:1107-19.e10

[68] Chang CH,O'Sullivan D,Noguchi T,Chen Q,Gubin MM,Tonc E,Pearce EJ.Metabolic competition in the tumor microenvironment is a driver of cancer progression.Cell2015;162:1229-41 PMCID:PMC4864363

[69] El-Khoueiry AB,Yau T,Kudo M,Kim TY,Trojan J,Meyer T,Yeo W,Anderson J,Lang L,Tang H,Melero I.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet2017;389:2492-502

[70] Liu CQ,Zhou ZG,Yu XJ,Lin J,Zhang YJ.Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma.Br J Cancer2018;

[71] Jung HI,Ji S,Bae SH,Chung JC,Lee MS.Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma.Cancer Res Treat2017;49:246-54 PMCID:PMC5266389

[72] Restifo NP,Rosenberg SA.Adoptive immunotherapy for cancer: harnessing the T cell response.Nat Rev Immunol2012;12:269-81

[73] Lefterova P,Buttgereit P,Scheffold C,Schmidt-Wolf IG.Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.J Immunother2000;23:304-10

[74] Pievani A,Pende D,Rambaldi A,Introna M.Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.Blood2011;118:3301-10

[75] Lee JH,Lim YS,Song TJ,Gwak GY,Kim YJ,Yoon JH.Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.Gastroenterology2015;148:1383-91.e6

[76] Chen CL,Zhao JJ,Li YQ,Pan K,Jiang SS,Zhang XF,Zhou ZQ,Xia JC.PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.Oncoimmunology2016;5:e1176653 PMCID:PMC5006896

[77] Xu L,Kim Y,Zhang YJ,Li YQ,Pawlik TM,Li SP.A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma.Oncoimmunology2015;5:e1083671 PMCID:PMC4839313

[78] Park JH,Gonen M,Sénéchal B,Sauter C,Santomasso B,Roshal M,Davila M,Sadelain M.Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia.N Engl J Med2018;378:449-59

[79] Maude SL,Buechner J,Boyer M,Bader P,Stefanski HE,Qayed M,Hiramatsu H,Davis KL,Nemecek ER,Peters C,Boissel N,Balduzzi A,June CH,Wood P,Leung M,Zhang Y,Lebwohl D,Grupp SA.Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.N Engl J Med2018;378:439-48

[80] Brown CE,Starr R,Wagner JR,Ostberg JR,Kilpatrick J,Kurien A,Wang X,D'Apuzzo M,Jensen MC,Chen M,Forman SJ.Regression of glioblastoma after chimeric antigen receptor T-cell therapy.N Engl J Med2016;375:2561-9 PMCID:PMC5390684

[81] Tanoue K,Watanabe N,Rana B,Brenner M.Armed oncolytic adenovirus expressing PD-L1 mini-body enhances anti-tumor effects of chimeric antigen receptor T cells in solid tumors.Cancer Res2017;77:2040-51 PMCID:PMC5392365

[82] Ahmed N,Hegde M,Ghazi A,Liu E,Ashoori A,Gray T,Liu H,Rainusso N,Mei Z,Gee A,Brenner MK,Wels WS,Anderson P.Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma.J Clin Oncol2015;33:1688-96 PMCID:PMC4429176

[83] Fesnak AD,Levine BL.Engineered T cells: the promise and challenges of cancer immunotherapy.Nat Rev Cancer2016;16:566-81 PMCID:PMC5543811

[84] Morgan RA,Wunderlich JR,Yang JC,Royal RE,Kammula US,Zheng Z,de Vries CR,Mavroukakis SA.Cancer regression in patients after transfer of genetically engineered lymphocytes.Science2006;314:126-9 PMCID:PMC2267026

[85] Johnson LA,Dudley ME,Yang JC,Kammula US,Sherry RM,Lee CC,Schwarz SL,Bishop RJ,Brewer CC,VanWaes C,Mathur A,Nathan DA,Rosenberg SA.Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.Blood2009;114:535-46 PMCID:PMC2929689

[86] Palmer DC,Gattinoni L,Paulos CM,Powell DJJr,Finkelstein SE,Yu Z,Rosenberg SA.Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity.Proc Natl Acad Sci U S A2008;105:8061-6 PMCID:PMC2409137

[87] Dargel C,Hasreiter J,Bockmann JH,Bohne F,Wilde S,Schendel DJ,Uckert W,Schiemann M,Heikenwälder M,Richter G,Protzer U.T cells engineered to express a T cell receptor specific for Glypican-3 to recognize and kill hepatoma cells in vitro and in mice.Gastroenterology2015;149:1042-52

[88] Qasim W,Gehring AJ,Schurich A,Zhan H,Gilmour K,Moriconi F,Mazzoni A,Morris E,Maini MK,Stauss H.Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient.J Hepatol2015;62:486-91

[89] Kageyama S,Miyahara Y,Ishihara M,Sugino S,Ishikawa T,Naota H,Shiraishi T,Tanabe M,Yoshioka H,Nukaya I,Takesako K,Shiku H.Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer.Clin Cancer Res2015;21:2268-77

[90] Rapoport AP,Binder-Scholl GK,Vogl DT,Badros AZ,Weiss B,Kulikovskaya I,Kronsberg S,Bond S,Brewer JE,Gerry AB,Williams D,Ribeiro L,Yanovich S,Yared J,Philip S,Siegel DL,Jakobsen BK,June CH.NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.Nat Med2015;21:914-21 PMCID:PMC4529359

[91] Chodon T,Chmielowski B,Wu Z,Ng C,Seja E,McCannel TA,Czernin J,Wang X,Cochran AJ,Wong DJ,Hamid O,Cohen PA,Mukherji B,Zack JA,Heath JR,Witte ON,Economou JS.Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.Clin Cancer Res2014;20:2457-65 PMCID:PMC4070853

[92] Kingwell K.CAR T therapies drive into new terrain.Nat Rev Drug Discov2017;16:301-4

[93] Gao H,Tu H,Jiang H,Kong J,Yang S,Li Z.Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.Clin Cancer Res2014;20:6418-28

[94] Yu M,Fan M,Shi B,Liu Y,Jiang H.Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma.Mol Ther2018;26:366-78

[95] Liu H,Xiang J,Green S,Zimdahl B,Cheng N,Liu B,Wang P,Jin L,Morales JF,Liu LX,Priceman SJ,Forman SJ,Liu C.Targeting alpha-fetoprotein (AFP)-MHC complex with CAR T-cell therapy for liver cancer.Clin Cancer Res2017;23:478-88

[96] Wang Y,Wu Z,Dai H,Liu Y,Lv H,Feng KC,Li XL.CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial.Oncoimmunology2018;7:e1440169 PMCID:PMC5993480